SCHEMBL1756087

SCHEMBL1756087

O=C1CCSc2ccccc2N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
NPC1 O15118 1/20 0.50
MAPK13 O15264 1/20 0.50
MAPK12 P53778 1/20 0.50
MAPK11 Q15759 1/20 0.50
MAPK14 Q16539 1/20 0.50
BRD4 O60885 1/20 0.49
CREBBP Q92793 1/20 0.49
ALDH1A1 P00352 4/20 0.48
GAA P10253 4/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
LMNA P02545 3/20 0.48
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9628996 0.89 MAPT (0.53) HDAC1HDAC8HDAC6NPC1MAPK13
SCHEMBL6632266 0.86 HDAC1 (0.42) HDAC1HDAC8HDAC6NPC1MAPK13
SCHEMBL6632268 0.82 LMNA (0.40) HDAC1HDAC8HDAC6NPC1MAPK13
SCHEMBL13323 0.80 ALDH1A1 (0.60) BRD4CREBBPALDH1A1GAAKMT2A
Hydrochloric Acid SCHEMBL30648399 0.78 ALDH1A1 (0.58) BRD4CREBBPALDH1A1GAAKMT2A
SCHEMBL8853709 0.77 ALDH1A1 (0.67) NPC1BRD4CREBBPALDH1A1GAA
SCHEMBL8853748 0.77 EPHX2 (0.70) HDAC1HDAC8HDAC6KMT2AMEN1
SCHEMBL9628939 0.76 NPC1 (0.53) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL5507140 0.75 HDAC1 (0.57) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL8853550 0.75 HDAC1 (0.57) HDAC1HDAC8HDAC6NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568959-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-18 EP claimed
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 EP claimed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 WO claimed
EP-1021190-B1 Amid derivatives as growth hormone release promotors KAKEN PHARMA CO LTD (JP) 2006-11-08 EP claimed
EP-1021190-A4 NOVEL AMIDE DERIVATIVES KAKEN PHARMA CO LTD (JP) 2004-08-18 EP claimed
EP-1359908-A1 QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-11-12 EP claimed
WO-2002056882-A1 QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-25 WO claimed
EP-1021190-A1 NOVEL AMIDE DERIVATIVES Kaken Pharmaceutical Co., Ltd. (JP) 2000-07-26 EP claimed
WO-1999009991-A1 NOVEL AMIDE DERIVATIVES KAKEN PHARMACEUTICAL CO., LTD. (JP) 1999-03-04 WO claimed
EP-0324181-B1 PROCESS FOR THE PREPARATION OF BENZOTHIAZEPINONE DERIVATIVES BAYER AG (DE) 1991-11-27 EP claimed
US-4948886-A Process for the preparation of benzothiazepinone derivatives BAYER AKTIENGESELLSCHAFT (DE) 1990-08-14 US claimed
EP-0324181-A1 Process for the preparation of benzothiazepinone derivatives BAYER AG (DE) 1989-07-19 EP claimed
US-20250367209-A1 IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE SOUTHERN RES INST (US) 2025-12-04 US disclosed
EP-4568959-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-18 EP disclosed
CN-119698413-A Bicyclic tetrahydrothiazepine derivatives 豪夫迈·罗氏有限公司 2025-03-25 CN disclosed
CN-119677733-A Bicyclic tetrahydrothiazepine derivatives 豪夫迈·罗氏有限公司 2025-03-21 CN disclosed
WO-1989005291-A1 ENANTIOSELECTIVE PREPARATION OF SUBSTITUTED AMINOTHIOPHENOL DERIVATIVES ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) 1989-06-15 WO disclosed
EP-0292824-A1 Process for the nuclear chlorination of aromatic hydrocarbons BAYER AG (DE) 1988-11-30 EP disclosed
EP-0158339-A2 1,5-Benzothiazephine derivatives, processes for preparing the same and pharmaceutical compositions Tanabe Seiyaku Co., Ltd. (JP) 1985-10-16 EP disclosed
EP-0158340-A2 Novel 1,5-benzothiazepine derivative, processes for preparing the same and pharmaceutical compositions Tanabe Seiyaku Co., Ltd. (JP) 1985-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250367209-A1 IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE MAPT, SORBS1, TARDBP HDAC1 629/4885HDAC8 1433/4885HDAC6 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.